Investors

To download our documents

Events

All events
30/05/2025

2025 ASCO Annual Meeting

May 30 - June 3rd, 2025

Read more
27/03/2025

Smallcap Event, Paris

March 27th, 2025, Paris

Read more
05/03/2025

Lusvertikimab & the Future of IBD: KOL Insights Post-ECCO

Save the date and join OSE Immunotherapeutics on 5 March at 6pm CET | 12pm ET for an exclusive webinar featuring top key opinion leaders (KOLs) and industry experts on…

Read more

Live stock price

OSE Immunotherapeutics is listed since 30th March 2015 on the regulated market of Euronext Paris

Share price

ISIN

FR0012127173

Ticker

OSE

Type of listing

Continuous

Number of outstanding shares

22,910,181 shares as of June 30, 2025

Eligibility

Eligible to Long-Only Deferred Settlement Service

Financial calendar

This calendar is indicative and may be amended. Financial results are published after market close (Euronext Growth Paris).

26 March 2025

Annual financial results 2024

25 September 2025

Cash position as of June 30, 2025

30 September 2025

General shareholders' meeting

15 October 2025

Full 2025 half-year interim financial results

Analysts

Read more
Edison
Arron Aatkar
Invest Securities
Jamila El Bougrini
Kepler Cheuvreux
Pierre-Alexandre Desir

Analyst reports

Read more
20/10/2025 Edison: Refocusing for the next phase
06/10/2025 All invests Securities: RETOUR DE VISIBILITÉ, LE PLAN DE MARCHE EST LANCÉ
17/09/2025 Kepler Cheuvreux : Completes the patient recruitment for the Combi-TED P2 study

Regulated information

Read more
30/10/2025 Nombre d'actions et de droits de vote au 30 septembre 2025
31/08/2025 Nombre d'actions et de droits de vote au 31 août 2025
31/07/2025 Nombre d'actions et de droits de vote au 31 juillet 2025

Professional Equality Index

Read more
25/02/2025 Professional Equality Index 2025
27/02/2024 Professional Equality Index 2024

General shareholders' meetings

Read more
11/09/2025

General Shareholders' Meeting - September 30, 2025

Results of the votes

Financial information and publications

Read more
2025 First-half 2025 semester report (in French)
2024 First-half 2024 semester report (in French)
2024 2023 Universal registration document

To receive OSE Immunotherapeutics’ latest news